Shared type 2 inflammation, divergent organ responses: mechanisms and therapeutic implications of biologics across atopic dermatitis, asthma, and eosinophilic esophagitis

Atopic dermatitis (AD), asthma, and eosinophilic esophagitis (EoE) are distinct inflammatory diseases of the skin, airways, and esophagus, respectively. These disorders can coexist and share overlapping immune pathways, but their manifestations and treatment responses differ substantially across organs. In this narrative review, we examine how differences in epithelial biology, structural cells, neural regulation, tissue remodeling, and injury patterns shape shared type 2 inflammation in each organ. We review clinical evidence for biologics targeting interleukin-4 receptor alpha (IL-4Rα), interleukin-13 (IL-13), interleukin-5 (IL-5) or its receptor alpha subunit (IL-5Rα), immunoglobulin E (IgE), and thymic stromal lymphopoietin (TSLP) across AD, asthma, and EoE. Particular attention is given to discordance between changes in biomarkers or tissue inflammation and improvements in symptoms or organ function. We also consider how current disease activity, pre-existing structural damage, drug exposure, and disease-specific outcome measures affect the assessment of treatment in patients with multimorbidity. Most cross-disease inferences still rely on separate single-disease trials, and prospective studies of patients with active involvement of multiple organs remain scarce. By critically integrating positive, negative, and discordant clinical trial findings, this review distinguishes disease-specific efficacy from direct evidence of concurrent multi-organ benefit. We examine how pathway dependence, tissue pathology, drug exposure, and methodological differences may contribute to discordance among biological, symptomatic, and functional outcomes. This synthesis provides an interpretive framework for assessing the applicability and limitations of existing evidence to patients with type 2 inflammatory multimorbidity and identifies priorities for future prospective studies.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1964415
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Shared type 2 inflammation, divergent organ responses: mechanisms and therapeutic implications of biologics across atopic dermatitis, asthma, and eosinophilic esophagitis

X. Wang, Qiuyan Chen, Hong Zhang, Xianbo Wu
Frontiers in Immunology
Asthma and respiratory diseases
article

Shared type 2 inflammation, divergent organ responses: mechanisms and therapeutic implications of biologics across atopic dermatitis, asthma, and eosinophilic esophagitis

X. Wang, Qiuyan Chen, Hong Zhang, Xianbo Wu
article en

Abstract

Atopic dermatitis (AD), asthma, and eosinophilic esophagitis (EoE) are distinct inflammatory diseases of the skin, airways, and esophagus, respectively. These disorders can coexist and share overlapping immune pathways, but their manifestations and treatment responses differ substantially across organs. In this narrative review, we examine how differences in epithelial biology, structural cells, neural regulation, tissue remodeling, and injury patterns shape shared type 2 inflammation in each organ. We review clinical evidence for biologics targeting interleukin-4 receptor alpha (IL-4Rα), interleukin-13 (IL-13), interleukin-5 (IL-5) or its receptor alpha subunit (IL-5Rα), immunoglobulin E (IgE), and thymic stromal lymphopoietin (TSLP) across AD, asthma, and EoE. Particular attention is given to discordance between changes in biomarkers or tissue inflammation and improvements in symptoms or organ function. We also consider how current disease activity, pre-existing structural damage, drug exposure, and disease-specific outcome measures affect the assessment of treatment in patients with multimorbidity. Most cross-disease inferences still rely on separate single-disease trials, and prospective studies of patients with active involvement of multiple organs remain scarce. By critically integrating positive, negative, and discordant clinical trial findings, this review distinguishes disease-specific efficacy from direct evidence of concurrent multi-organ benefit. We examine how pathway dependence, tissue pathology, drug exposure, and methodological differences may contribute to discordance among biological, symptomatic, and functional outcomes. This synthesis provides an interpretive framework for assessing the applicability and limitations of existing evidence to patients with type 2 inflammatory multimorbidity and identifies priorities for future prospective studies.

Frontiers in ImmunologyVol. 17
Chengdu Sport University (CN), General Administration of Sport of China (CN), Chengdu University (CN), Yanbian University Hospital (CN), Chengdu University of Traditional Chinese Medicine (CN)
National Natural Science Foundation of China
Good health and well-being
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon